Consolidation with high-dose chemotherapy and autologous stem cell transplantation (ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma, based on randomized trials showing improved progression-free survival with autologous transplantation after combination chemotherapy induction. These trials were performed before novel agents were introduced; subsequently, combinations of immunomodulatory drugs and proteasome inhibitors as induction therapy have significantly improved rates and depth of response. Ongoing randomized trials are testing whether conventional autologous transplantation continues to improve responses after novel agent induction. Although these results are awaited, it is important to review strategies for improving outcomes after ASCT. Conditioning before ASCT with higher doses of melphalan and combinations of melphalan with other agents, including radiopharmaceuticals, has been explored. Tandem ASCT, consolidation, and maintenance therapy after ASCT have been investigated in phase III trials. Experimental cellular therapies using ex vivo-primed dendritic cells, ex vivo-expanded autologous lymphocytes, Killer Immunoglobulin Receptor (KIR)-mismatched allogeneic natural killer cells, and genetically modified T cells to augment ASCT are also in phase I trials. This review summarizes these strategies and highlights the importance of exploring strategies to augment ASCT, even in the era of novel agent induction.
INTRODUCTION
Myeloma represents just over 1% of all cancers and despite a recent increase in available therapeutics, the disease remains incurable with an estimated 5-year survival just over 50% [1] . Randomized controlled trial (RCT) evidence from France and the United Kingdom demonstrated improved disease response and overall survival (OS) after autologous hematopoietic stem cell transplantation (ASCT) compared with after conventional chemotherapy [2, 3] . However, subsequent trials from France, the United States, and Spain did not show an OS benefit, although Fermand et al. [4] did show an improvement in progression-free survival (PFS) [4] [5] [6] . The differences in outcomes between groups may be accounted for by prolonged use of conventional chemotherapy in the study by Fermand et al. and a high rate of ASCT salvage therapy at relapse in the study by Barlogie et al. [6] . A Dutch trial demonstrated that after treatment with intermediate-dose melphalan, further treatment with ASCT did not improve outcomes [7] . These trials support the use of high-dose alkylating agents in myeloma treatment. For patients who are fit for high-dose therapy (approximately one-third of newly diagnosed patients), treatment with chemotherapy conditioning followed by ASCT has been the standard of care, and the standard conditioning regimen has been a single dose of intravenous melphalan at 200 mg/m 2 [8] . There has been much interest in augmenting conditioning but no single regimen has been shown to improve outcomes in a randomized trial. Adjunctive strategies have also been explored: second tandem ASCT; consolidation and maintenance chemotherapy; attempts to augment immune responses after transplantation; and new drugs, particularly monoclonal antibodies. This review will evaluate the strategies employed and make recommendations for further research in this area.
NOVEL AGENT INDUCTION
Induction for transplantation-eligible patients with immunomodulatory drugs (IMiD) (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib) has improved response rates before ASCT. The HOVON50 trial demonstrated that substituting thalidomide for vincristine in the vincristine, doxorubicin, and dexamethasone (VAD) regimen could increase pre-ASCT ORR from 54% to 72% [9] . The benefit conferred by thalidomide combinations in induction was confirmed by the Myeloma IX and Total Therapy 2 trials [10, 11] . The Intergroupe Francophone Myélome (IFM) 2005-01 trial demonstrated that bortezomib and dexamethasone was also superior to VAD, increasing the pre-ASCT response rate to 79% from 63% [12] , and a similar improvement with bortezomib-based induction was observed in the HOVON65/GMMGHD4 trial [13] . Cavo et al. tested the addition of bortezomib to thalidomide plus dexamethasone (VTD), and this combination of both IMiD and proteasome inhibitor significantly improved both pre-ASCT ORR (93% versus 79%) and PFS [14] . This combination, VTD, is also superior to bortezomib, cyclophosphamide, and dexamethasone, producing pre-ASCT ORR of 92% versus 83% in a phase III trial [15] . Combining lenalidomide with bortezomib plus dexamethasone (VRD) produced an ORR of 94% in a phase II IFM study [16] . An ongoing phase II study of carfilzomib, lenalidomide, and dexamethasone for both induction and maintenance obtained an ORR pre-ASCT of 98% and demonstrated no unexpected toxicity [17] .
The improvement in responses seen with newer induction programs has prompted further trials after induction comparing upfront ASCT with a nontransplantation option of novel agent consolidation followed by maintenance. Recently published phase III trials comparing ASCT with lenalidomide-containing regimens found ASCT confers superior PFS, although at a median follow up of 52 months, no differences in OS were observed [18, 19] . An ongoing French/ American RCT (the IFM/DFCI 2009 study) compares ASCT plus 2 cycles of VRD with 5 cycles of VRD alone, and results from the French cohort show superior complete response (CR) rate (58% versus 46%) and 3-year PFS (61% versus 48%) in the ASCT arm [20] . EMN02/HO95 is a European 2 × 2 factorial RCT, currently recruiting patients to compare ASCT versus bortezomib, melphalan and prednisolone (VMP) intensification and then consolidation with VRD versus no consolidation [21] . The possible merits of a delayed transplantation strategy are being evaluated in the PADIMAC phase II study for patients achieving very good partial response (VGPR) or CR after bortezomib, doxorubicin, and dexamethasone: up to 20% of patients had negative minimal residual disease (MRD) after induction, and survival outcomes are awaited [22] .
CONDITIONING FOR ASCT
High-dose melphalan 200 mg/m 2 (mel200) delivered as a single dose for conditioning has been shown in a randomized trial to be less toxic and at least as effective as melphalan 140 mg/m 2 (mel140) plus 8 Gy total body irradiation (TBI) [8] , and mel200 has since remained the gold standard for single ASCT in patients with normal renal function. Escalating the dose of melphalan above 200 mg/m 2 is prohibitively toxic to the gastrointestinal tract. Minimizing oral mucositis with protective agents amifostine [23] and palifermin, a keratinocyte growth factor, may facilitate dose increases to 280 mg/m 2 for a proportion of patients [24] . However, wide variability in melphalan exposure due to pharmacokinetic differences has been reported. In a pharmacokinetic study of high-dose melphalan in 100 patients, higher mucositis rates and improved disease response were seen in patients with higher exposure to melphalan, as measured by increased area under the curve of both total and unbound melphalan [25] .
Melphalan and Chemotherapeutic Agent Combinations
A number of chemotherapeutic agents and combinations with mel200 have been tested in clinical studies, but the majority of these studies enrolled fewer than 100 patients and were nonrandomized studies, so it is difficult to draw significant conclusions (Table 1) .
Regarding alkylating agents in combination with melphalan, oral busulfan is demonstrably too toxic, as 8% of patients in a Spanish study developed veno-occlusive disease, with a case fatality rate of 25% [26] . The intravenous busulfan formulation introduced in 2003 reduces hepatic exposure via the portal circulation, and a nonrandomized study (n = 153) comparing mel140 plus busulfan 9.6 mg/kg i.v. with mel200 suggested a small benefit in terms of PFS but increased treatment-related mortality, with neither difference reaching statistical significance [27] . Adding cyclophosphamide 120 mg/kg to mel200 worsens outcomes [28] , and further addition of idarubicin progressively increases treatment-related mortality to 20% [29] . An RCT of cyclophosphamide, oral busulfan, and total marrow irradiation versus 2 consecutive ASCT with mel200 found the chemoradiotherapy regimen to be more toxic with no significant improvement in efficacy [30] . Reports from MD Anderson Cancer Centre using mel140 plus topotecan and cyclophosphamide in combination show outcomes comparable to mel200 but a controlled comparison is required [31, 32] . The addition of carmustine to mel200 was found to be safe in single-arm studies, with comparable PFS and OS to previously published mel200 studies [33, 34] . More recently, bendamustine, which has shown single agent activity in relapsed myeloma, was combined with mel200 at escalated doses reaching 225 mg/m 2 with only 1 dose-limiting toxicity in the first 100 days after transplantation [35] .
Melflufen is a dipeptide prodrug of melphalan, which by virtue of increased intracellular hydrolysis is concentrated in myeloma cells. Melflufen induces apoptosis in melphalanresistant cells and is highly effective in mouse models [36] . A phase I/II trial of melflufen and dexamethasone in relapsedrefractory myeloma is ongoing, but initial results are encouraging with an ORR of 60% [37] . Based on these encouraging results, melflufen as a conditioning regimen before ASCT should be explored in future trials.
Topoisomerase inhibitors (doxorubicin, idarubicin, mitoxantrone, topotecan) have been tested in combination with melphalan as conditioning, although in vitro data on the combination are limited. The addition of cyclophosphamide and idarubicin to mel200 was shown in an RCT to markedly increase treatment-related mortality [29] , but adding cyclophosphamide and topotecan to mel140 produced promising outcomes in an uncontrolled series [32] . Two small phase II studies of mitoxantrone combined with melphalan (combined n = 55) suggest outcomes comparable to mel200 [38, 39] .
Arsenic trioxide with ascorbic acid has been explored in a randomized trial recruiting 48 patients, combined with mel200. There was no difference in response rate or survival, but no additional toxicity was noted [40] .
Melphalan with Proteasome Inhibitors and IMiDs
Synergistic myeloma cell kill in vitro has been noted with the combination of melphalan and bortezomib [41, 42] . Bortezomib, by inhibiting the proteasome, interferes with DNA repair pathways and inhibitors of apoptosis, thus sensitizing cells to DNA-damaging agents such as melphalan.
There are currently no randomized data for the addition of bortezomib to ASCT conditioning. A French nonrandomized phase II study found that adding 1 mg/m 2 bortezomib to mel200 improved CR rates from 11% to 35% [43] ; however, in contrast, 2 other small studies (combined n = 27) using nonrandomized control patients observed no difference in response rate. Reassuringly, no increase in toxicity was observed [44, 45] . A phase I study suggests that bortezomib is more effective when given after melphalan dosing, rather than before, with an increase in CR rates from 11% to 30% [46] . In an uncontrolled series, 36% of patients with primary refractory myeloma obtained a CR after tandem ASCT with bortezomib given after melphalan [47] . Lenalidomide at TRM indicates treatment-related mortality; Mel180, melphalan 180 mg/m 2 . * Denote a statistically significant difference between arms (P < .05).
higher-than-licensed doses has been combined with mel200 in a phase I study of relapsed/refractory myeloma and no lenalidomide-related dose-limiting toxicities were observed, with 8 of 21 patients (38%) achieving ≥ CR [48] . Carfilzomib is a recently licensed irreversible proteasome inhibitor, which has been studied in phase III trials in relapsed/ refractory myeloma [49] ; a phase I/II trial is currently underway in combination with melphalan as a conditioning regimen (CARAMEL trial, NCT01842308).
Augmentation with Radiotherapy/Radiopharmaceuticals
TBI displays excessive toxicity in trials, but targeted radiotherapy shows promising early results. Phase I/II trials of radiophosphonates (containing 153 Sm or 166 Ho, respectively) added to mel200 conditioning showed no change in outcomes with little toxicity, though renal failure due to thrombotic microangiopathy was seen with doses > 30 Gy of the 166 Holmium conjugate [50, 51] . The combination of bortezomib with the 153 Samarium conjugate demonstrated promising synergy in mice and merits further clinical investigation [52] . CD66 is expressed on myeloma cells as well as the myeloid lineage: an anti-CD66 radioconjugate monoclonal antibody is selective for bone marrow and appears to be safe in a phase I trial [53] , with results from the phase II trial awaited. Radio-conjugated CD20 antibodies show additional toxicity in phase I when added to mel200 for conditioning ( 90 Y-ibritumomab) [54] and limited efficacy when used as a single agent ( 131 I-tositumomab), which may relate to low CD20 expression on myeloma cells, with higher response rates correlating with expression of CD20 [55] . Radio-conjugate antibodies against CD38 and CD138 have been studied in animal models, but clinical trials are awaited [56, 57] . Tomotherapy (radiotherapy delivered from many emitters arranged radially to focus treatment, analogous to computed tomography [CT] scans) has hitherto only been studied in leukemias and lymphomas [58] , but studies in myeloma are underway. This would require a head-to-head comparison with molecularly targeted radiotherapy in future.
TANDEM TRANSPLANTATION
Two consecutive cycles of high-dose chemotherapy, with each cycle followed by hematopoietic stem cell transplantation/rescue (tandem ASCT), has been extensively investigated by both European and US cooperative groups in an attempt to improve responses ( Table 2 ). The Arkansas group have undertaken a series of Total Therapy Trials using intensive treatment including tandem ASCT, which have achieved impressive results, with a 41% CR rate and median OS of 68 months in Total Therapy 1 [59, 60] . However, these studies were uncontrolled and patient selection was wholly at the discretion of the investigators. A fuller retrospective dataset from the same center, which included patients treated off study protocols, demonstrated inferior results, but on multivariate analysis, a second transplantation was still associated with prolonged PFS and OS [61] .
Most randomized trials comparing single with tandem ASCT have shown no benefit in OS from tandem stem cell transplantation [7, [62] [63] [64] [65] (reviewed by Kumar et al. [66] ). Many of these trials utilized nonstandard conditioning regimens (eg, oral busulfan or TBI), which have since been shown to be inferior to standard mel200 [7, 62, 63, 65] . However the GMMG-HD2 trial, which used tandem standard mel200 ASCT, showed no difference in survival [64] . The only trial to show a significant benefit for both PFS and OS was the IFM-94 study, but the outcomes (in both groups) were poor compared with those from more recent trials using newer agents as part of the treatment protocol [62] . In a nonrandomized comparison between the Dutch protocol (single transplantation) and the German protocol (tandem ASCT), the latter was superior for OS, but regional variations in demographics and treatment could account for this difference [67] . Subgroup analyses suggest there may be a survival advantage from a second ASCT in those patients who fail to achieve a deep response to the first ASCT [62, 63] . In the majority of trials, treatment-related mortality is higher in the tandem ASCT arm, and in addition to this acute risk, there may be an increased risk of long-term complications, such as second malignancies and myelodysplastic syndrome, although it is not clear that ASCT increases that risk over high-dose conventional chemotherapy [68] . The deep responses achieved with proteasome inhibitors and IMiD-based conditioning regimens, and wider use of consolidation and maintenance therapies, have both limited the use of tandem stem cell transplantation.
CONSOLIDATION
Relapse remains inevitable after ASCT and consolidation therapy after transplantation has been investigated as a way of prolonging PFS by deepening post-transplantation response. Several phase II and phase III studies of post-ASCT consolidation have been performed over the last 5 years (Table 3) , but there is a lack of randomized data to support its efficacy. Only 1 phase III trial is placebo controlled [69] and uncontrolled studies are not instructive because responses improve over months after ASCT regardless of further treatment. In a phase II comparison with historical controls, patients receiving cyclophosphamide, thalidomide, and dexamethasone consolidation achieved better responses at 12 months (72% ≥ VGPR versus 51%) [70] . In a phase III RCT, bortezomib as a single agent improved response and PFS but with no improvement in OS [69] . In a phase III trial of adding bortezomib to thalidomide and dexamethasone (ie, VTD versus thalidomide and dexamethasone for both induction and consolidation, there was no OS benefit, but 3-year PFS increased from 56% to 68%, commensurate with deepening response [14] . The consistent finding of deeper responses with delayed progression but no effect on OS likely reflects more effective salvage treatment at relapse for the control group.
There are no randomized data on lenalidomide-based consolidation, but in an RCT of lenalidomide maintenance, all patients from both arms first received 2 months of lenalidomide consolidation and over this period, the rate of ≥ VGPR increased from 58% to 69% [71] . A phase II study of lenalidomide, bortezomib, and dexamethasone in both induction and consolidation demonstrated good responses and impressive survival data, with an estimated 77% 3-year PFS [16] . Results from a phase II study of carfilzomib, lenalidomide, and dexamethasone for induction, consolidation and maintenance (with lower doses of carfilzomib) showed that 88% of patients were MRD-negative after 4 cycles of consolidation, which will hopefully be reflected in future improved survival data [17] . Survival benefits from consolidation strategies after ASCT have yet to be confirmed in randomized studies.
MAINTENANCE
Relapse after ASCT is primarily due to residual myeloma cells that continue to survive and proliferate, and maintenance therapy aims to control this process, by giving continuous lowdose therapy until relapse (Table 4) . However, a concern is that although progression is delayed on maintenance, at relapse the disease could be refractory to further treatment and so benefits in OS would be limited. Such benefits must be balanced against toxicity, quality of life, and cost effectiveness, given the long duration of maintenance approaches. Earlier maintenance studies did not include any consolidation, and the survival plots often diverge early, which suggests that most benefit is gained early after transplantation. It is unclear if there are advantages to commencing maintenance after an effective course of consolidation treatment. Interferon alpha had been used as a maintenance agent for many years, but it is uniformly poorly tolerated. Used as maintenance therapy after conventional chemotherapy, interferon alpha modestly prolonged PFS with no effect on OS [72] but the US Intergroup S9321 trial found that it made no difference on progression or survival after ASCT [6] . A therapeutic dose of prednisolone conferred a survival benefit when used after VAD-based conventional chemotherapy [73] , but glucocorticoids as monotherapy in the post-ASCT population are redundant now, given the improved clinical activity and tolerability observed with IMiDs and proteasome inhibitors. In a phase III comparison between dexamethasone and interferon maintenance, the dexamethasone group responded very badly to melphalan/dexamethasone at relapse, presumably because of selection of resistant clones [74] .
Thalidomide maintenance has been subjected to a number of phase III trials, conferring a 10% increase in the 4-year survival rate compared with no maintenance [75] , and in an RCT comparing thalidomide plus prednisolone versus prednisolone alone, OS was increased by 10% at 3 years [76] . A smaller RCT of similar design found a nonsignificant trend towards increased survival in the thalidomide arm [77] . However, an RCT of thalidomide plus prednisolone versus no maintenance found no OS difference and highlighted worse qualityof-life scores in the maintenance group [78] . In all of these trials, adverse events of grade 3 or 4 were much more common in the thalidomide arm; this is reflected in a thalidomide discontinuation rate of 30% within 1 year in the study by Spencer et al. [76] .
In a joint German/Dutch trial comparing induction and maintenance with bortezomib versus vincristine-based induction and thalidomide maintenance, there were improved response rates and PFS, but the OS difference barely reached statistical significance (P = .049) on a multivariate analysis [13] . There was no difference in response during the maintenance phase, between the 2 arms. In a post-hoc analysis, patients with renal impairment gained a significant benefit from the bortezomib arm [79] . Two large RCTs of lenalidomide maintenance against placebo showed an early benefit in PFS, which in the Cancer and Leukemia Group B (CALGB) study prompted early termination [80] . The CALGB trial (n = 460) subsequently showed a small OS benefit, but no OS difference was seen in the IFM study (n = 614). This study gave both arms 2 cycles of lenalidomide consolidation at a higher dose before randomization [71] and the Kaplan-Meier OS plot of the CALBG study diverges early and is parallel thereafter, which suggested that any benefit in OS is derived from the first few months on lenalidomide. Both studies agreed that there are considerable toxicities from lenalidomide, with increased hematological adverse events and secondary cancers seen in the lenalidomide groups.
Combining bortezomib with lenalidomide in maintenance confers a high side effect burden, but in a phase II study demonstrated good results in patients with high risk myeloma or plasma cell leukemia, with 93% OS at 3 years, and no patients stopped maintenance due to toxicity [81] . A nonrandomized comparison between sequential cohorts receiving bortezomib and dexamethasone with either lenalidomide or thalidomide, as maintenance for low-risk myeloma found no difference in survival or relapse rates [82] . Maintenance with VRD is yet to be studied in a phase III randomized trial.
NEW AGENTS
Histone deacetylase inhibitors (vorinostat and panobinostat) have been explored in phase III trials of relapsed/refractory myeloma in combination with bortezomib. Vorinostat demonstrated limited activity [83] but panobinostat in combination with bortezomib and dexamethasone increased PFS with OS data yet to show a significant difference [84] . Vorinostat has been combined with lenalidomide for maintenance after ASCT in a phase I study, with 14 of the 16 subjects having grade 3 or 4 adverse events during maintenance [85] , which compares unfavorably with lenalidomidemonotherapy maintenance trials [71, 80] .
Several new monoclonal antibodies, antibody-drug conjugates, and small molecules are in phase II and III trials for both newly diagnosed and relapsed/refractory myeloma. Adding elotuzumab (targeting SLAMF7, Signaling Lymphocyte Activation Molecule Family member 7) to lenalidomide and dexamethasone increased the response rate from 66% to 79% in relapsed or refractory patients and PFS from 14.9 months to 19.4 months in a phase III trial [86] . A phase I trial of elotuzumab in combination with bortezomib induced responses in 48% of patients with relapsed/refractory myeloma [87] . The anti-CD38 daratumumab looks promising in phase I/II trials [88] [89] [90] , and 3 phase III trials of daratumumab plus various chemotherapy regimens are currently recruiting in newly diagnosed and relapsed populations. The antibody-drug conjugates lorvotuzumab mertansine (with lenalidomide/dexamethasone, ORR 59%) [91] and indatuximab ravanstine (with lenalidomide/dexamethasone, ORR 78%) [92] and the AKT inhibitor afuresertib (with bortezomib/ dexamethasone, ORR 49%) [93] demonstrate activity in phase I trials in relapsed/refractory patients. Phase I trials of anti-PD1 monoclonal antibodies in combination with IMiDs [94, 95] , the anti-CD74 conjugate milatuzumab-doxorubicin, and an anti-CD200 antibody are currently ongoing in relapsed myeloma.
None of these new agents are currently being investigated as part of an ASCT treatment protocol. Monoclonal antibodies are not particularly myelosuppressive: elotuzumab has lower neutropenia rates than the control group [86] and although a minority of patients receiving daratumumab developed low cell counts, this was not dose dependent [90] . Given this low toxicity, they are attractive targeted therapies for use in consolidation and maintenance phases to suppress residual myeloma clones.
IMMUNOTHERAPY AND CELLULAR THERAPY
The reconstitution of the immune system after ASCT is an opportunity to augment the immune response against myeloma. Natural killer (NK) cells, components of the innate immune system with the potential to kill cancer cells, reconstitute quickly after ASCT, and the number of NK cells at day 30 correlates with PFS after ASCT [96] . Lymphocyte populations recover gradually over 1 year or more, and the early populations are abnormal, with an excess of CD8 + T cells and few CD4
+ T cells, which have a narrow T cell-receptor repertoire. The lymphodepletion brought on by high-dose therapy causes levels of cytokines IL-5 and IL-17 to rise, which in turn drive extrathymic proliferation of CD4 + T cells. This expansion of T cells in the absence of regulatory T cell expansion may facilitate an effective antimyeloma adaptive immune response.
Maintenance therapy with interferon alpha was the earliest IMiD therapy, augmenting the cellular antimyeloma response and, although modestly effective as maintenance after ASCT, it was not adopted because of poor tolerability [6] . Another approach used cyclosporin in a small population of mixed hematological malignancies for 1 month after ASCT, leading to a reaction akin to acute graft-versus-host disease, which was associated with improved disease-free survival but no OS difference [97] .
Vaccine strategies include myeloma dendritic cell (DC) fusion, autologous serum-loaded DCs, myeloma-peptidestimulated T cells, and idiotypic DNA vaccination (Figure 1) . A phase I trial of autologous DC-myeloma cell fusion cells injected into myeloma patients found these induced expansion of myeloma-specific T cells in vivo and stabilized disease progression in 11 of 16 patients [98] . A small trial from the Mayo clinic of ex vivo-stimulated DCs accompanying ASCT found improved survival compared with matched historical controls [99] , and a small Czech study looking at ex vivo stimulated DCs as monotherapy in pretreated patients found a modest improvement in outcomes [100] . Two small trials of myeloma peptide vaccines followed by ex vivo T cell expansion and reinfusion showed these to be safe and effective at inducing lymphocyte responses [101, 102] , but no effect on clinical outcomes could be discerned from these small groups, with only the former including a control arm. DNA vaccines (variable regions of paraprotein heavy and light chains, fused to tetanus toxin, in an expression vector) appear to be safe in phase I trials, though they only elicited an anti-idiotype immune response in 4 of 14 subjects [103] . These vaccine strategies merit further investigation in clinical trials.
Engineered T cells with chimeric antigen receptors (CAR), which combine the antigen-binding fragment of antibodies with the signaling domains of the T cell receptor, have been used with some success against advanced leukemias and lymphomas [104, 105] . CAR T cells targeting CD19 have been used as part of ASCT in 10 myeloma patients who were heavily pretreated; 4 have responded to date, with 1 patient achieving a stringent CR that has lasted over 12 months [106] . CAR T cells against CD38 can effectively kill myeloma cells in vitro [107] , and phase I trials are ongoing for these (NCT01886976), and chimeric anti-kappa light chain T cells (NCT00881920). Toxicities from CAR T cell therapies include an infusional cytokine release syndrome and potential off target effects. In mouse studies, ex vivo-expanded NK cells can inhibit growth of myeloma tumors [108] . This concept is explored in phase I studies of autologous expanded NK cells (with chemotherapy but without transplantation) in relapsed myeloma patients (NCT01313897 and NCT01884688). Haploidentical but KIRmismatched allogeneic NK cells are also being investigated as an adjunct to ASCT [109] .
TRIAL ENDPOINTS
Overall survival remains the gold standard endpoint for trials in myeloma, but survival rates have improved, with over one-third of newly diagnosed patients living longer than 10 years in the United Kingdom [110] , so OS is a late endpoint for trials to report. The CR rate has historically correlated poorly with OS [111] [112] [113] and clearly does not take account of quality of life aspects, which are affected by increasingly prolonged myeloma therapy regimens. In early trials, time to progression did correlate with OS, but with consolidation treatment, this association is no longer seen [13, 71, 74, 77, 78] . PFS2, the time from first treatment to second relapse, takes account of tumor resistance induced by the first line of treatment, and to date studies have shown it is prolonged in association with PFS [114, 115] , but it has not yet been validated as a surrogate for OS, and still takes years of follow-up to report mature data. In contrast, recent ASCT trials have shown an association between the depth of response and OS [116, 117] , and this is particularly the case for prolonged (> 3 years) CR [118] . However, the CR rate still remains a relatively insensitive surrogate for OS, and as median survival continues to improve, particularly for transplantationeligible populations, we have to adopt earlier endpoints to study the gamut of new agents entering the field. Measuring MRD by multiparameter flow cytometry accurately predicts OS in patients who have achieved a CR [119, 120] and represents an opportunity to vastly shorten the time required for trials of aggressive treatment to report. 18 Fflurodeoxyglucose positron emission tomography (PET) CT scanning is also a predictor of PFS and OS, both after induction [121] and after ASCT [122] . Its predictive power is independent of CR status, but further studies are needed combining MRD measurement and PET CT to determine whether both independently provide prognostic information. These trials will still need long-term follow-up to identify late adverse events, the impact on quality of life, and hopefully confirm the predictive power of these new endpoints.
OUTSTANDING QUESTIONS AND FUTURE TRIAL DESIGNS
We await with interest the final results of several studies testing ASCT against a block of novel agent consolidation therapy. Both PFS and OS remain crucial endpoints, as the latter depends on the ability to salvage patients after relapse. Future trials should be randomized and stratified by genetic risk to provide clear guidance for treatment decisions. Trials should consider using new endpoints, such as MRD negativity (by high-throughput flow cytometry or genetic sequencing) and sustained CR rates in addition to PFS and OS. A number of key questions should be addressed in the debate over ASCT as standard practice after induction therapy:
1. Is there a more effective conditioning regimen than mel200? 2. Does a block of consolidation therapy between ASCT and maintenance therapy improve clinical outcomes versus maintenance alone? 3. Does the addition of a proteasome inhibitor to IMiDbased maintenance improve outcomes? 4. What role should new monoclonal antibodies and kinase inhibitors play to improve post-ASCT response? 5. Are MRD negativity, sustained CR, and PET CT-negativity valid surrogate endpoints for OS?
CONCLUSION
ASCT remains the standard of care for eligible newly diagnosed myeloma patients, despite improvements in induction chemotherapy with IMiDs and proteasome inhibitors. Early trials of ASCT achieved complete remission lasting >10 years in a small minority of patients [59] , and with advances in induction protocols, it is likely that with ASCT consolidation, this proportion will continue to increase. The most promising strategies for improving conditioning therapy, on the basis of phase II studies, are the addition of proteasome inhibitors or topoisomerase inhibitors, but these require confirmation in randomized trials. Melflufen and radio-conjugate drugs have yet to be assessed as part of conditioning, but they hold theoretical promise. Tandem ASCT upfront may improve responses in patients not achieving CR after their first transplantation, but it does not offer an OS benefit over delayed second ASCT at relapse for most patients. We await with interest long-term OS data to see if there is a benefit from lenalidomide maintenance. Treatment after ASCT, with both an IMiD and a proteasome inhibitor in combination, has achieved impressive results in phase II studies, but this has not yet been systematically tested in a phase III study. Several monoclonal antibodies and kinase inhibitors are promising in early clinical trials and, although these targeted drugs are unlikely to replace ASCT, they may find a role in post-ASCT consolidation. Experimental therapies to augment cellular immune responses to myeloma have demonstrated biological activity in patients refractory to other lines of treatment, and despite high potential for toxicity, they merit investigation in the post-ASCT period, when patients are lymphocyte depleted and the burden of disease is low. These new therapeutic strategies could substantially increase the proportion of patients achieving long-term disease control after ASCT. At the same time, clinical trials need to report more rapidly and hopefully, if MRD negativity continues to robustly translate into survival in reported studies, then the adoption in clinical trials of MRD detection as a key endpoint will greatly facilitate this.
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